Insiders Trades
Quantum-Si Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Mar 2026.
Quantum-Si Inc: what insiders have been doing
Quantum-Si Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 10 insiders published 37 filings.
Purchases and sales both appear in the filings: 2 purchases (2 insiders, €485k) and 24 sales (4 insiders, €336k). The totals do not cover 6 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. At €395k, the purchase published on 9 March 2026 by Kummeth Charles R. is the largest of the period. Among those who bought: 2 senior executives.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 37 filings, this issuer sits above that mark. Since 2021, the database holds 12 purchases and 49 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 2.4 m USD of revenue and -101.3 m USD of net income.
The data flag 2 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 9 March 2026, 223 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
98
Thresholds
n/a
Buy Volume
€991,097
12 ops. · all time
Sell Volume
€4M
49 ops. · all time
Who traded when
BuySaleHawkins Jeffrey Alan11 sales
Keyes Jeffry R.11 sales
LaPointe Christian9 sales
Vieceli John S.6 sales
Rothberg Jonathan M2 sales
Bennett Todd C.1 sale
+2 other insiders
Since the insiders bought
- +1.9%Entry US$1.04 · Close at T+90 US$1.06
- +1.9%Entry US$1.04 · Close at T+90 US$1.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Quantum-Si Inc Buy (bullish), based on 3 analysts. Average price target: US$2.30.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,913 of 24,148 companies
21.4
score / 100
Value5
Quality37
FCF yld-40%
Earn yld-41%
EV/EBITDA·
ROE-49%
Gross mgn47%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.12
Analyst consensus
3 analystsBuy
US$1.00Target US$2.30(+105%)US$4.00
Income statement
RevenueUS$2.4M
Gross profitUS$1.2M47% margin
EBITDA-US$92.9M-3814% margin
Net income-US$101.3M-4160.1% margin
Valuation
PER (forward)-3.2x
P/Book1.4x
Beta3.22
Balance sheet & cash
Market capUS$245.1M
Total debtUS$4.2M
Free Cash Flow-US$97.2M
Debt / Equity2%
Profitability & ownership
ROE-49.1%
ROA-25.7%
% insiders10.5%
% institutions24.8%
Last declaration on 23 September 2026
Declarations98 total
29,852 shares@ US$0.75745.3% of flowClass A Common StockSEC144:0001505034-26-000004
7,665 shares@ US$0.75742.1% of flowClass A Common StockSEC144:0001557736-26-000004
14,516 shares@ US$0.75743.3% of flowClass A Common StockSEC144:0001856912-26-000003
20,143 shares@ US$0.75583.6% of flowClass A Common StockSEC:0001140361-26-037481:0
9,709 shares@ US$0.76081.7% of flowClass A Common StockSEC:0001140361-26-037481:1
5,172 shares@ US$0.75581.4% of flowClass A Common StockSEC:0001140361-26-037478:0
2,493 shares@ US$0.76080.7% of flowClass A Common StockSEC:0001140361-26-037478:1
9,795 shares@ US$0.75582.2% of flowClass A Common StockSEC:0001140361-26-037476:0
4,721 shares@ US$0.76081.1% of flowClass A Common StockSEC:0001140361-26-037476:1
22,621 shares@ US$0.92824.9% of flowClass A Common StockSEC144:0001505034-26-000003
8,233 shares@ US$0.92822.8% of flowClass A Common StockSEC144:0001557736-26-000003
15,588 shares@ US$0.92824.4% of flowClass A Common StockSEC144:0001856912-26-000002
30,223 shares@ US$0.928221.6% of flowClass A Common StockSEC144:0002032947-26-000002
7,794 sharesClass A Common StockSEC:0001140361-26-026294:0
7,794 sharesClass A Common StockSEC:0001140361-26-026294:1
11,310 sharesClass A Common StockSEC:0001140361-26-026285:0
11,311 sharesClass A Common StockSEC:0001140361-26-026285:1
4,116 sharesClass A Common StockSEC:0001140361-26-026290:0
4,117 sharesClass A Common StockSEC:0001140361-26-026290:1
83,712 shares@ US$1.006419.2% of flowClass A Common StockSEC:0001140361-26-016152:0
83,712 shares@ US$0.99519.0% of flowClass A Common StockSEC:0001140361-26-016152:1
37,382 shares@ US$1.006413.6% of flowClass A Common StockSEC:0001140361-26-016155:0
37,381 shares@ US$0.99513.5% of flowClass A Common StockSEC:0001140361-26-016155:1
4,233 shares@ US$0.84831.3% of flowClass A Common StockSEC:0001140361-26-010949:0
5,849 shares@ US$0.84831.5% of flowClass A Common StockSEC:0001140361-26-010946:0
25 of 98 declarations
About Quantum-Si Inc
Quantum-Si Inc. is a U.S.-based healthcare technology company listed on the Nasdaq under the ticker QSI, with warrants trading as QSIAW. Headquartered in Branford, Connecticut, United States, the company was founded in 2013 around a disruptive thesis: applying semiconductor and electronics design principles to protein analysis in order to make proteomics more accessible, faster, and more informative for research laboratories. Following its 2021 business combination with HighCape Capital Acquisition Corp., Quantum-Si gained public-market visibility and established itself as a specialized player in next-generation proteomics.
Quantum-Si’s business model centers on a proprietary single-molecule detection platform applied to protein sequencing. The company currently markets its Platinum product line, which includes benchtop instruments and associated consumable kits for academic, pharmaceutical, and translational research customers. Its offering is designed to move beyond traditional proteomics workflows, which are often labor-intensive and multistep, by providing high-resolution functional and dynamic protein insights. Strategically, Quantum-Si is working to simplify proteomics workflows and build an installed base that can support recurring revenue from consumables and kits.
Read moreShow less
From a competitive standpoint, Quantum-Si operates in an emerging market and faces indirect competition from established players in sequencing, mass spectrometry, and broader multi-omics platforms. Its differentiation lies in a hardware-led approach built on semiconductor chips and monomolecular protein detection. That positioning may prove attractive if the platform continues to validate technically and commercially, but it remains early in the commercialization curve. The company’s customer base is primarily global scientific and research organizations, with commercial exposure centered on the United States and other advanced research markets through direct sales, partnerships, and distribution relationships.
Recent milestones suggest continued platform development and commercialization efforts. In 2024 and 2025, Quantum-Si highlighted progress on Proteus, a next-generation hardware platform expected to reach commercial launch later in the product cycle. The company has also continued to expand its sequencing kit portfolio and pursue collaborations aimed at improving proteomics data utility. Recent press releases and SEC filings indicate management remains focused on product performance, adoption, and industrialization. For French-speaking investors, Quantum-Si remains a high-risk growth story with typical exposure to adoption risk, financing needs, dilution potential, and an uncertain path to sustained profitability.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
